Skip to content Skip to navigation

24 March: World TB Day: Can India stop drug-resistant TB too?

By bobbyramakant |

This World Tuberculosis (TB) Day (24 March) is another opportunity for people of India to review their TB responses. Drug susceptible TB is treatable, curable and with proper programme interventions, it is possible to believe in the theme of World TB Day: 'I can stop TB'. Can we say the same for drug-resistant TB?

Drug-resistant TB has been recorded in the world at the highest levels ever according to the World Health Organization (WHO) report (Anti-Tuberculosis Drug Resistance in the World, February 2008).

DOTS (directly-observed treatment short-course), is the internationally recommended TB control strategy that includes standardized case detection, treatment and patient support. It requires consistent drug supply and effective monitoring systems. According to WHO, drug resistant TB is a symptom of poor programme performance. If we hope to change the outcome, and decrease the proportion of drug resistant TB, doesn't the DOTS model need to be adapted or its implementation improved? More of the same might only compound the TB drug resistance threat.

The African, South-East Asian and Western pacific regions account for 83% of total TB case notifications according to the Global Tuberculosis Control report of WHO (March 2008). China, India and Indonesia are home to two-in-three of the world's TB cases. The Africa region has the highest TB incidence rate. These countries are expanding coverage of its TB programme at record-breaking speed. In its shadow, drug resistance is also upping the pace.

The proportion of resistance to at least one anti-TB drug (any resistance) was found to be as high as 56.3% in Azerbaijan.

Multi drug-resistant TB (MDR-TB) is defined as TB with resistance to isoniazid and rifampicin, the two most powerful first line anti-TB drugs. MDR-TB patients have significantly poor outcomes than patients with drug susceptible TB.

Global estimates indicate that 4.8% of TB cases were of MDR-TB (about half a million MDR-TB patients). Currently treatment is available only to one out of ten MDR-TB patients and 90% of MDR-TB patients cannot have access to treatment they need today.

About 50% of MDR-TB cases are in India and China because of large population. In Africa, hard-hit by HIV, the proportion of TB drug-resistance is no less alarming. In former Soviet Union, almost half of all TB cases are resistant to at least one anti-TB drug and every fifth case of TB will be of MDR-TB.

Extensively drug-resistant TB (XDR-TB) is virtually untreatable and likely to emerge where second-line anti-TB drugs are widely and inappropriately used. XDR-TB is more expensive and difficult to treat than MDR-TB and outcomes for patients are much worse with mortality rates very high. So far 46 countries have reported XDR-TB with UK reporting the first XDR-TB case last week.

Studies suggest that transmission of TB, especially the drug-resistant strains is more likely to take place where people living with HIV (PLHIV) congregate. Healthcare settings, for example those for anti-retroviral (ARV) delivery, is one such place where improper infection control can put PLHIV at risk of contracting TB. TB is the most common opportunistic infection and leading cause of death for PLHIV. Improving infection control in healthcare settings is clearly vital, doable and potentially life saving.

In many countries insufficient laboratory capacity to test drug-resistance is a serious impediment in scaling up TB programmes. Even the new WHO report on TB drug-resistance had data only from 6 African countries because other countries had no laboratory capacity to provide data on anti-TB drug-resistance. Developing laboratories to provide rapid diagnosis of anti-TB drug-resistance, particularly for PLHIV, is of utmost importance to improve TB responses.

Not only more and better TB drugs and diagnostics in the public sector are urgently needed but also better strategies to make TB control programmes work more effectively for the most vulnerable and hard to reach communities are essential to improving treatment adherence and, as a consequence, reducing drug resistance.

  • 9158 reads

Add new comment

Other Contents by Author

Prevent an independent PMI from worsening the tobacco pandemic

In anticipation of the expected announcement on 30 January 2008 of the timing of Philip Morris International's spin-off, public health organizations worldwide say there is heightened urgency for governments to enact comprehensive laws to control Philip Morris and other tobacco companies. "The unleashing of Philip Morris International from Philip Morris USA poses the risk that Philip Morris International will become even more predatory in pushing its toxic products to young people worldwide," says Anna White, of the U.S.-based corporate accountability group Essential Action, "An independent Philip Morris International, which is likely to be based in Switzerland, will no...

30% of new HIV infections in Asia associated with injecting drug use

Thirty percent of all new HIV infections in Asia are associated with injecting drug use, estimates the joint United Nations Programme on HIV/AIDS (UNAIDS). Nearly half of the world's estimated 13 million drug users live in Asia where injecting drug use is a major factor fuelling HIV transmission. Most of the global supply of opium and heroin is produced in Asia where vulnerable groups who inject drugs form a significant population engaged in high risk behavior such as sharing contaminated injecting equipment and unprotected sex leading to HIV infection. Some Asian countries report HIV prevalence among injecting drug users (IDUs) as high as 85% while others that previously reported little...

Jattha marching to connect people's struggles in India

A 'jattha' will begin on 26 January 2008 from Nandigram in West Bengal marching and connecting all people's struggles and movements across the states of India to end in Gorai, Mumbai, Maharashtra on 4 February 2008. A mid high-point will be when it reaches Narmada valley where one of the biggest people's movements since India's independence struggle is still ensuing."The Nandigram struggle has created history. The adverse impact of imperialist globalization and the primacy of capital and market on India's polity is clearly visible not only in Nandigram struggle but also from the struggle by farmers, workers, Dalits, Adivasis across the country. The illusory development slogans churned...

Tobacco advertisements of Philip Morris' brands removed as per law

Activists to go to court for legal action against Godfrey PhillipsThe point-of-sale tobacco advertisements that were violating the Indian tobacco control Act in Goa, India, were removed by the evening of 16 January 2008.In the lead up to the removal of these advertisements, activists and media had reported that the advertisements of a cigarette brand of world's largest tobacco company - Philip Morris' Indian subsidiary were blatantly violating 'The Cigarette and Other Tobacco Products Act 2003" and the rulings for the point-of-sale tobacco advertising.Clearly due to the mounting pressure, these tobacco advertisements were removed by last evening."I'm extremely happy that the...

Philip Morris' Indian subsidiary violates Tobacco Control Act

An advertisement of a tobacco product in Goa by the world's largest tobacco company Philip Morris' subsidiary in India blatantly violates the Indian tobacco control Act."Tobacco co mpanies are undermining [tobacco control] legislations in many countries" had said Dr. Douglas Betcher, Head of Tobacco Free Initiative of the World Health Organization (WHO) recently in a meeting on the global tobacco treaty.The rulings for point-of-sale tobacco advertising in accordance with 'The Cigarettes and Other Tobacco Products (Prohibition of Advertisement and Regulation of Trade and Commerce, Production, Supply and Distribution) Act, 2003', came into effect on 1 January 2006. The Rules envisage...